Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Scientists describe antibodies that protect against large variety of flu viruses

10.08.2012
The work is a key step toward 'universal' vaccine and therapies against flu

A team led by scientists at The Scripps Research Institute and Crucell Vaccine Institute in the Netherlands describes three human antibodies that provide broad protection against Influenza B virus strains. The same team had previously reported finding broadly neutralizing antibodies against Influenza A strains.

The isolation of the new broadly neutralizing antibodies, which was reported the journal Science's advance online edition, Science Express, on August 9, paves the way for researchers to develop a universal antibody-based flu therapy for use in severe infections or to protect hospital staff during an outbreak. Importantly, these antibodies may provide key clues to the design of an active universal flu vaccine—designed to protect long-term against flu viruses, not just against the current season's strains.

"To develop a truly universal flu vaccine or therapy, one needs to be able to provide protection against influenza A and influenza B viruses, and with this report we now have broadly neutralizing antibodies against both," said Ian A. Wilson, the Hansen Professor of Structural Biology at Scripps Research, who was senior investigator for the new study with Crucell's Jaap Goudsmit and Robert Friesen.

One of the newly discovered antibodies will be of special interest to flu researchers, because it appears to protect against essentially all influenza B and influenza A strains. "It's the only one in the world that we know of that has been found to do this," said Wilson.

Looking for the Missing Pieces

Influenza B viruses are considered less dangerous than Influenza A viruses, and have been less intensively studied because they have less capacity to mutate into deadly pandemic strains. However, influenza B viruses account for a significant part of the annual flu illness burden in humans.

To find broadly protective antibodies against Influenza B, the team at Crucell generated a large collection of flu antibodies from the immune cells of volunteers who had been given a seasonal flu vaccine. The researchers then screened this collection for antibodies that could bind to a wide variety of influenza B strains.

Three of the antibodies they found in this manner—CR8033, CR8071, and CR9114—protected mice against normally lethal doses of the two major influenza B strains. CR9114 also protected mice against influenza A viruses, including the H1N1 subtype that killed about 17,000 people in a 2009 pandemic. The fact that these antibodies protected against a variety of flu strains suggested they mark functionally important sites, or "epitopes," on the virus that are relatively unchanging (conserved) from one flu strain to the next.

Wilson's team at Scripps Research characterized the newly discovered antibodies' binding sites on influenza viruses using electron microscopy and X-ray crystallography techniques. They found that CR8033 binds to a highly conserved epitope—a functionally important site—on the "head" of the hemagglutinin protein, a structure that studs the outer coat of flu viruses and allows the viruses to stick to vulnerable cells. CR8071 binds to the base of the hemagglutinin head. Most antibodies that bind to the hemagglutinin head and neutralize influenza do so by blocking the virus's attachment to host cells.

"The unique thing about these two antibodies is that they neutralize flu viruses chiefly by preventing virus particles from exiting infected cells," said Nick Laursen, a research associate in Wilson's laboratory who was a lead author of the study.

A Weak Point on the Virus

Antibody CR9114 turned out to bind to a site on the hemagglutinin stem. "It prevents the hemagglutinin protein from undergoing the shape-change needed for the virus to fuse to the outer membrane of a host cell," said Cyrille Dreyfus, a Wilson lab research associate who also was a lead author of the study. "This appears to be a real weak point of the virus, because this epitope is highly conserved among influenza A subtypes as well as influenza B."

Wilson notes that in a study published in 2009 his laboratory determined the structure of another Crucell antibody that broadly neutralizes influenza A viruses by binding to essentially the same site on the hemagglutinin stem—but in a subtly different way, so that it fails to get a grip on influenza B viruses, too. "With some tweaking of that antibody's binding domains, we might have been able to get a broader effect like CR9114's," Wilson said.

The viral epitope to which CR9114 binds will now be studied extensively by researchers as a target for vaccines and therapies, because it is the only one found so far that is broadly vulnerable to neutralization on both influenza A and B viruses.

Remarkably, CR9114 performed poorly against influenza B viruses in initial lab-dish tests known as microneutralization assays, which test the ability of an antibody to protect cells from viral infection. Yet CR9114 was clearly effective under more realistic conditions in mice, even at low doses. Because it attacks the stem rather than the head of flu virus hemagglutinins, CR9114 also failed to show effects in a widely used test known as the hemagglutinin-inhibition assay.

"As we move towards design of a universal flu vaccine, we need to find more inclusive assays to screen for antibodies such as CR9114, which may be highly effective but have novel mechanisms for neutralization that cannot be detected by the current methods used in influenza vaccine development," Goudsmit said.

The other authors of the paper, "Highly conserved protective epitopes on Influenza B viruses," were Ted Kwaks, David Zuijdgeest, Miriam V. Bujny, Mandy Jongeneelen, Remko van der Vlugt, Mohammed Lamrani, Hans J.W.M. Korse, Eric Geelen, Özcan Sahin, Martijn Sieuwerts, Just P.J. Brakenhoff, Ronald Vogels, and Wouter Koudstaal of the Crucell Vaccine Institute; Olive T.W. Li, Leo L. M. Poon and Malik Peiris of the University of Hong Kong; and Reza Khayat, Damian C. Ekiert, Jeong Hyun Lee, Zoltan Metlagel, and Andrew B. Ward of Scripps Research.

Support for the research was provided by a number of sources including the National Institute of General Medical Sciences' Protein Structure Initiative (U54 GM094586), the National Institutes of Health's National Center for Research Resources (P41 RR017573), and the U.S. Department of Energy (contract DE-AC02- 06CH11357).

Mika Ono | EurekAlert!
Further information:
http://www.scripps.edu

More articles from Life Sciences:

nachricht O2 stable hydrogenases for applications
23.07.2018 | Max-Planck-Institut für Chemische Energiekonversion

nachricht Scientists uncover the role of a protein in production & survival of myelin-forming cells
19.07.2018 | Advanced Science Research Center, GC/CUNY

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Future electronic components to be printed like newspapers

A new manufacturing technique uses a process similar to newspaper printing to form smoother and more flexible metals for making ultrafast electronic devices.

The low-cost process, developed by Purdue University researchers, combines tools already used in industry for manufacturing metals on a large scale, but uses...

Im Focus: First evidence on the source of extragalactic particles

For the first time ever, scientists have determined the cosmic origin of highest-energy neutrinos. A research group led by IceCube scientist Elisa Resconi, spokesperson of the Collaborative Research Center SFB1258 at the Technical University of Munich (TUM), provides an important piece of evidence that the particles detected by the IceCube neutrino telescope at the South Pole originate from a galaxy four billion light-years away from Earth.

To rule out other origins with certainty, the team led by neutrino physicist Elisa Resconi from the Technical University of Munich and multi-wavelength...

Im Focus: Magnetic vortices: Two independent magnetic skyrmion phases discovered in a single material

For the first time a team of researchers have discovered two different phases of magnetic skyrmions in a single material. Physicists of the Technical Universities of Munich and Dresden and the University of Cologne can now better study and understand the properties of these magnetic structures, which are important for both basic research and applications.

Whirlpools are an everyday experience in a bath tub: When the water is drained a circular vortex is formed. Typically, such whirls are rather stable. Similar...

Im Focus: Breaking the bond: To take part or not?

Physicists working with Roland Wester at the University of Innsbruck have investigated if and how chemical reactions can be influenced by targeted vibrational excitation of the reactants. They were able to demonstrate that excitation with a laser beam does not affect the efficiency of a chemical exchange reaction and that the excited molecular group acts only as a spectator in the reaction.

A frequently used reaction in organic chemistry is nucleophilic substitution. It plays, for example, an important role in in the synthesis of new chemical...

Im Focus: New 2D Spectroscopy Methods

Optical spectroscopy allows investigating the energy structure and dynamic properties of complex quantum systems. Researchers from the University of Würzburg present two new approaches of coherent two-dimensional spectroscopy.

"Put an excitation into the system and observe how it evolves." According to physicist Professor Tobias Brixner, this is the credo of optical spectroscopy....

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Leading experts in Diabetes, Metabolism and Biomedical Engineering discuss Precision Medicine

13.07.2018 | Event News

Conference on Laser Polishing – LaP: Fine Tuning for Surfaces

12.07.2018 | Event News

11th European Wood-based Panel Symposium 2018: Meeting point for the wood-based materials industry

03.07.2018 | Event News

 
Latest News

Enabling technology in cell-based therapies: Scale-up, scale-out or program in-place

23.07.2018 | Health and Medicine

Abrupt cloud clearing events over southeast Atlantic Ocean are new piece in climate puzzle

23.07.2018 | Earth Sciences

The Maturation Pattern of the Hippocampus Drives Human Memory Deve

23.07.2018 | Science Education

VideoLinks
Science & Research
Overview of more VideoLinks >>>